ARISTOCORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARISTOCORT (ARISTOCORT).
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
| Metabolism | Hepatic; primarily via CYP3A4 oxidation and glucuronidation. |
| Excretion | Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor. |
| Half-life | Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues. |
| Protein binding | 68-79% bound to albumin and corticosteroid-binding globulin (CBG); concentration-dependent. |
| Volume of Distribution | Vd ~1.4 L/kg; indicates extensive tissue distribution, including high uptake in liver and fat. |
| Bioavailability | Oral: 20-30% (first-pass effect); IM: 80-100% (depot formulation); Topical: variable (1-5% systemically absorbed); Intra-articular: minimal systemic absorption. |
| Onset of Action | Oral: 1-2 hours; IM: 24-48 hours (ester hydrolysis required); Intra-articular: 12-24 hours; Topical: hours to days depending on lesion. |
| Duration of Action | Oral: 1-2 days; IM (triamcinolone acetonide): 1-2 weeks; Intra-articular: 1-4 weeks; Topical: days to weeks based on formulation and condition. |
| Molecular Weight | 434.48 |
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
| Dosage form | CREAM |
| Renal impairment | No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment due to increased risk of fluid retention and hypertension. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50%. Child-Pugh C: Avoid use or reduce dose by 50-75% with close monitoring. |
| Pediatric use | Intramuscular: 0.11-1.6 mg/kg/day divided every 12-24 hours; Intra-articular: 2.5-15 mg depending on joint size; Oral: 0.1-0.5 mg/kg/day divided every 6-12 hours. |
| Geriatric use | Start at lowest effective dose; monitor for hyperglycemia, osteoporosis, fluid retention, and increased infection risk; use minimally effective duration. |
| 1st trimester | Corticosteroids are associated with increased risk of cleft palate and other congenital anomalies. Use only if clearly needed. |
| 2nd trimester | May cause fetal growth restriction and adrenal suppression. Use only if potential benefit justifies risk. |
| 3rd trimester | Similar risks as second trimester; may cause neonatal adrenal suppression. Use only if clearly indicated. |
Clinical note
Comprehensive clinical and safety monograph for ARISTOCORT (ARISTOCORT).
| Placental transfer | Corticosteroids cross the placenta to varying degrees. Triamcinolone crosses the placenta, with fetal levels approximately 40-50% of maternal levels. Higher doses increase transfer. |
| Breastfeeding | Triamcinolone (ARISTOCORT) is excreted into breast milk in small amounts. No adverse effects reported in infants. However, high doses or prolonged use may cause suppression of infant adrenal function. Use with caution and monitor infant for growth and development. |
■ FDA Black Box Warning
Intrathecal administration may cause arachnoiditis, meningitis, and other severe adverse events.
| Serious Effects |
Systemic fungal infectionHypersensitivity to triamcinolone or any componentAdministration of live or live-attenuated vaccinesIdiopathic thrombocytopenic purpura (for intramuscular use)
| Precautions | Immunosuppression and increased infection risk; adrenal suppression; Cushing's syndrome with prolonged use; osteoporosis; growth retardation in children; masking of infections; increased intraocular pressure; cataract formation. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they can increase systemic exposure of triamcinolone. Limit high-sodium foods to reduce fluid retention and hypertension. Increased potassium loss may occur; consider potassium-rich foods if not contraindicated. Alcohol may increase risk of gastrointestinal ulceration. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Corticosteroids cross placenta. First trimester: increased risk of cleft palate (~3.5x), dose-dependent; may also cause fetal growth restriction, adrenal suppression. Second/third trimester: risk of preterm labor, preeclampsia, gestational diabetes, fetal HPA axis suppression with prolonged use. Use only if benefit outweighs risk (e.g., severe asthma, SLE). |
| Fetal Monitoring | Maternal: blood pressure, blood glucose (gestational diabetes screening), serum electrolytes, signs of infection, bone density if long-term. Fetal: ultrasound for growth (corticosteroids linked to IUGR), gestational age assessment; neonatal: monitor for adrenal insufficiency if exposed late in pregnancy (withdrawal symptoms: hypoglycemia, poor feeding, lethargy). |
| Fertility Effects | Potential to suppress HPA axis and affect menstrual cycle (oligomenorrhea, anovulation) at high doses. Not directly studied for infertility; reversible upon dose reduction/cessation. No evidence of permanent impairment. |
| Clinical Pearls | ARISTOCORT (triamcinolone acetonide) is a potent corticosteroid. For intra-articular use, avoid overuse in a single joint to prevent steroid arthropathy. In dermatology, do not use on infected lesions unless proper antimicrobial therapy is initiated. Systemic absorption can occur with topical application, especially under occlusion or on large areas. Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use. Taper dose when discontinuing after long-term therapy to avoid adrenal crisis. |
| Patient Advice | Do not stop taking this medication suddenly; follow your doctor's tapering schedule. · Avoid live vaccines while on this medication. · Report any signs of infection (fever, sore throat) or worsening of underlying condition. · For topical use: apply a thin layer, avoid occlusive dressings unless instructed, and do not use on broken skin or open wounds. · Limit sodium intake and monitor for fluid retention. · Do not use for longer than prescribed; long-term use can lead to serious side effects. |